Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma
- 3 February 2022
- journal article
- letter
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (2) , 402-406
Abstract
To describe a case of ocular inflammation associated with dabrafenib and trametinib chemotherapy for cutaneous melanoma by using a multimodal image approach. We report on a 51-year-old woman with Vogt-Koyanagi-Harada-like syndrome, which occurred while she was undergoing treatment with dabrafenib and trametinib for cutaneous melanoma. The patient complained of sudden, bilateral vision loss of 2 days’ duration. Anatomical and functional improvement was observed after administration of systemic steroids and cessation of chemotherapy. Later on, 6 weeks after restarting dabrafenib, she had an episode of granulomatous anterior uveitis, which was successfully managed with topical mydriatics and steroids. Strict follow-up with multimodal imaging was performed until recovery. This report emphasizes the importance of strict ophthalmological follow-up with multimodal imaging in patients receiving dabrafenib and trametinib, and the need for a multidisciplinary approach in the management of ocular inflammation during chemotherapy.Keywords
Funding Information
- funding associated
This publication has 7 references indexed in Scilit:
- A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanomaEuropean Journal of Ophthalmology, 2020
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialThe Lancet Oncology, 2020
- Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapyTherapeutic Advances in Medical Oncology, 2020
- Evaluation of Retinal Pigment Epithelium Layer Change in Vogt-Koyanagi-Harada Disease With Multicontrast Optical Coherence TomographyInvestigative Ophthalmology & Visual Science, 2019
- OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORSRetina, 2019
- HLA‐DRB1*04:05 in two cases of Vogt–Koyanagi–Harada disease‐like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapyThe Journal of Dermatology, 2018
- Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With VemurafenibAmerican Journal of Ophthalmology, 2014